Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ceftriaxone-dosis for ikke-kritisk samfundserhvervet lungebetændelse (DC-CAP)

2. november 2026 opdateret af: Jonathan Baghdadi, University of Maryland, Baltimore

Pragmatisk Randomiseret Undersøgelse, der Vurderer Doseringen af Ceftriaxon for Samfundserhvervet Lungebetændelse uden for Intensiv Afdeling

Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.<p>

Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.

Studieoversigt

Detaljeret beskrivelse

This study will be a pragmatic trial in which prospectively enrolled patients will be randomly assigned to Ceftriaxone dosed either 1 gram or 2 grams daily. When a clinician in the emergency department or non-intensive care inpatient ward orders Ceftriaxone and selects 'community-acquired pneumonia' as the indication, the electronic health record software used at the study sites (Epic) will prompt the ordering clinician to opt into the study. No direct patient contact will occur.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

900

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
      • Baltimore, Maryland, Forenede Stater, 21201
        • University of Maryland Medical Center - Midtown Campus
        • Kontakt:
      • Glen Burnie, Maryland, Forenede Stater, 21061
        • UM Baltimore Washington Medical Center
        • Kontakt:
      • Towson, Maryland, Forenede Stater, 21204
        • University of Maryland St. Joseph Medical Center
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Evaluated in the emergency department or within 72 hours of hospitalization
  • Prescribed Ceftriaxone for community-acquired pneumonia

Exclusion Criteria:

  • Planned or present admission to an intensive care unit
  • Respiratory failure requiring mechanical ventilation, non-invasive ventilation such as bilevel positive airway pressure, or high flow nasal cannula

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Low Dose Ceftriaxone

Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit.

Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of non-critical community-acquired pneumonia.

Aktiv komparator: Moderate Dose Ceftriaxone

Intravenous Ceftriaxone will be dosed 2 grams daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit.

Intravenous Ceftriaxone will be dosed at 2 grams daily per institutional guidance for treatment of community-acquired pneumonia.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Antibiotic escalation within 5 days of randomization
Tidsramme: The outcome will be assessed 5 days after enrollment

Defined by increasing the dose or frequency of Ceftriaxone, starting additional antibiotics not ordered concurrently with Ceftriaxone, or switching Ceftriaxone to an antibiotic with a broader spectrum up activity >24 hours after enrollment; antibiotic changes made on the calendar day of discharge in preparation for discharge alive from the hospital will not be considered escalation

The outcome will be assessed 5 days after enrollment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to stability
Tidsramme: The outcome will be assessed 90 days after enrollment

Time in days from randomization until stability defined by temperature < 38, heart rate < 100, respiratory rate < 24, oxygen saturation > 90%, systolic blood pressure ≥ 90, and return to baseline mental status based on Glasgow Coma Score over a 24-hour period

The outcome will be assessed 90 days after enrollment
Clinical deterioration within 10 days of randomization
Tidsramme: The outcome will be assessed 10 days after enrollment

Defined by admission to an intensive care unit, mechanical ventilation, or in-hospital mortality on any hospital day, or supplemental oxygen >5 L after hospital day 3 during the index encounter

The outcome will be assessed 10 days after enrollment
Ceftriaxone-associated toxicity within 10 days of randomization
Tidsramme: The outcome will be assessed 10 days after enrollment

Defined by new development of Hemoglobin < 10, elevated liver enzymes or or total bilirubin, clinically significant diarrhea (represented by Clostridioides difficile testing), or rash (represented by consult to dermatology)

The outcome will be assessed 10 days after enrollment
Ranked composite outcome
Tidsramme: The outcome will be assessed 30 days after enrollment

Rank 1 (highest rank) = no antibiotic escalation, clinical deterioration, or Ceftriaxone-associated toxicity Rank 2 = antibiotic escalation without clinical deterioration or Ceftriaxone-associated toxicity Rank 3 = Ceftriaxone-associated toxicity without clinical deterioration Rank 4 = clinical deterioration without 30-day mortality Rank 5 = 30-day mortality

The outcome will be assessed 30 days after enrollment
Duration of antibiotics
Tidsramme: The outcome will be assessed 90 days after enrollment

Defined as the total days of antibiotic therapy during the hospital encounter

The outcome will be assessed 90 days after enrollment
Hospital length of stay
Tidsramme: The outcome will be assessed 90 days after enrollment

Duration of hospitalization in days

The outcome will be assessed 90 days after enrollment
All-cause readmission
Tidsramme: The outcome will be assessed 90 days from enrollment

Readmission for any reason within 30 days of hospital discharge

The outcome will be assessed 90 days from enrollment
In-hospital mortality
Tidsramme: The outcome will be assessed 90 days after enrollment

In-hospital death or discharge to hospice

The outcome will be assessed 90 days after enrollment
Clostridioides difficile infection
Tidsramme: The outcome will be assessed 90 days after enrollment

Positive laboratory test for Clostridioides difficile within 30 days of randomization

The outcome will be assessed 90 days after enrollment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. februar 2027

Primær færdiggørelse (Anslået)

31. maj 2028

Studieafslutning (Anslået)

30. september 2028

Datoer for studieregistrering

Først indsendt

10. april 2026

Først indsendt, der opfyldte QC-kriterier

16. april 2026

Først opslået (Faktiske)

17. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. april 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner